ClinicalTrials.gg
CompletedNCT00869336Updated Jun 21, 2011

Multicenter Study of the Efficacy and Safety of Luliconazole Cream in Tinea Pedis (Athlete's Foot)

A Phase 2 interventional study of Luliconazole Cream 1% - 2 wks and Placebo Comparator -2 wks in Tinea Pedis, sponsored by Tinea Pharmaceuticals. Completed at 4 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2011-06-21.

Sponsored by Tinea Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
147
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 30 studies in Tinea Pedis with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Tinea Pedis · United States.

Enrollment
17th of 29
147 · median 160
Started
2009
with 1 other
Phase 2
9 of 30
1 open now
Registered
9th of 30
by date
Lead sponsor
2 of 30
Tinea Pharmaceuticals

Among the 30 studies in Tinea Pedis with a site in United States, this one is the 17th largest by enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2009, is one of 9 in phase 2, and was the 9th registered.

Tinea Pedis

73 studies on the registry are indexed under Tinea Pedis; 8 are open to participants now.

Browse Tinea Pedis studies →

Open to participants now

1 of the 30 studies in Tinea Pedis with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Tinea Pedis studies recruiting now, 2 set no upper age limit and 3 stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Tinea Pedis with a site in United States, or all of them as a file.
02

Study summary

To examine the safety and optimal duration of Luliconazole Cream 1% treatments for 14 days or 28 days to achieve "complete clearance" at 2 weeks post treatment.

03

Conditions studied

  • Tinea Pedis

Browse trials for

Keywords

  • Tinea Pedis
  • Athlete's Foot
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects of either gender must be 12 years of age or older.
  2. Subjects with a clinical diagnosis of interdigital tinea pedis on one or both feet characterized by clinical evidence of a tinea infection (at least moderate erythema, moderate scaling, and mild pruritus) based on signs and symptoms.
  3. Subjects with a mycological diagnosis of interdigital tinea pedis confirmed by the detection of fungal hyphae on a microscopic KOH wet mount
  4. Females of must have a negative urine pregnancy test and must agree to use an effective form of

Exclusion criteria

Exclusion Criteria:

  1. Subjects with moccasin (dry type) tinea pedis; with concomitant onychomycosis of the fingernails and/or toenails on the evaluated foot, with severe dermatophytoses, a concurrent tinea infection or bacterial skin infection on the evaluated foot;
  2. Female subjects who are pregnant and/or nursing or planning a pregnancy during the course of the trial.
  3. Subjects who are (due to disease, e.g., or medications
  4. Subjects with a history of intolerance or to imidazole compounds or the inactive components of the cream;
  5. Subjects with a life-threatening condition (e.g., deficiency syndrome, cancer, unstable angina, or myocardial infarction) within the last 6 months.
  6. Subjects using the following medications:

    1. topical antifungal agent within 30 days of the baseline visit
    2. systemic antifungals within 8 weeks of the baseline visit (8 months for oral terbinafine)
    3. topical in treatment area(s) within 30 days of the baseline visit.
    4. systemic corticosteroids within 30 days of the baseline visit;
    5. any other topical medicated topical treatments to the treatment area(s) within 7 days of baseline visit.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
147 participants (actual)

Study arms

  • Experimental
    Luliconazole Cream 1% - 2 wks

    Daily treatment with Luliconazole Cream 1% for 2 weeks

    Drug: Luliconazole Cream 1% - 2 wks

  • Experimental
    Luliconazole Cream 1% - 4 wks

    Daily treatment with Luliconazole Cream 1% for 4 weeks

    Drug: Luliconazole Cream 1% - 4 wks

  • Placebo comparator
    Placebo Comparator - 2 wks

    Daily treatment with Vehicle Cream for 2 weeks

    Drug: Placebo Comparator -2 wks

  • Placebo comparator
    Placebo Comparator - 4 wks

    Daily treatment with Vehicle Cream for 4 weeks

    Drug: Placebo Comparator - 4 wks

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of subjects who achieve complete clearance at 2 weeks post treatment

    Time frame: Two weeks post treatment

Secondary outcomes

  1. Proportion of subjects who achieve effective treatment at 2 and 4 weeks post treatment

    Time frame: 2 and 4 weeks post treatment

07

Study locations

4 sites
  • Fridley, Minnesota 55432, United States
  • Portland, Oregon 97210, United States
  • Austin, Texas 78759, United States
  • College Station, Texas 77840, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2009
First posted
Mar 26, 2009
Start
Mar 2009
Primary completionActual
Sep 2009
CompletionActual
Sep 2009
Results delay requested
Jun 6, 2011
Last update
Jun 21, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 21, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00869336
Lead sponsor
Tinea Pharmaceuticals
First posted
Mar 26, 2009
Start date
Mar 2009
Primary completion
Sep 2009
Completion
Sep 2009
Last update
Jun 21, 2011

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Luliconazole

Start the discussion